Effects of paroxetine on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia

Therapeutic Drug Monitoring

Volumn 34, Issue 2, 2012, Pages 188-192

  Nemoto, Kenji ^a   Mihara, Kazuo ^a   Nakamura, Akifumi ^a   Nagai, Goyo ^a   Kagawa, Shoko ^a   Suzuki, Takeshi ^a   Kondo, Tsuyoshi ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

aripiprazole; CYP2D6; dehydroaripiprazole; drug interaction; paroxetine

Indexed keywords

ARIPIPRAZOLE; BIPERIDEN; DEHYDROARIPIPRAZOLE; FLUNITRAZEPAM; PAROXETINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; JAPANESE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETER; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT DURATION;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BASAL GANGLIA DISEASES; CHROMATOGRAPHY, LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HUMANS; JAPAN; MALE; MASS SPECTROMETRY; MIDDLE AGED; PAROXETINE; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; SCHIZOPHRENIA; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84862832249     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31824a31e6     Document Type: Article

References (27)

1. Shapiro DA, Renock S, Arrington E, at al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28:1400-1411. (Pubitemid 41070874)
2. Harrison TS, Perry CM. Aripiprazole a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64:1715-1736. (Pubitemid 39128008)
3. Kerwin R, Millet B, Herman E, et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole (STAR) study. Eur Psychiatry. 2007; 22:433-443. (Pubitemid 47600616)
4. Caccia S. N-dealkylation of arylpiperazine derivatives: disposition and metabolism of the 1-aryl-piperazines formed. Curr Drug Metab. 2007;8: 612-622. (Pubitemid 47209098)
5. Kubo M, Koue T, Inaba A, et al. Influence of itraconazole coadministration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole. Drug Metab Pharmacokinet. 2005;20: 55-64.
6. Suzuki T, Mihara K, Nakamura A, et al. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit. 2011;33:21-24.
7. Nakamura A, Mihara K, Nagai G, et al. Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia. Ther Drug Monit. 2009;31:575-578.
8. Kirschbaum KM, Mü ller MJ, Malevani J, et al. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry. 2008;9:212-218.
9. Wagstaff AJ, Cheer SM, Matheson AJ, et al. Paroxetine: an update of its use in psychiatric disorders in adults. Drugs. 2002;62:655-703. (Pubitemid 34264033)
10. Jockers-Scherü bl, MC, Bauer A, Godemann F, et al. Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study. Int Clin Psychopharmacol. 2005;20:27-31. (Pubitemid 40105546)
11. Alfaro CL, Lam YWF, Simpson J, et al. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. J Clin Psychopharmacol. 1999;19:155-163. (Pubitemid 29161961)
12. Alfaro CL, Lam YWF, Simpson J, et al. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol. 2000;40:58-66.
13. Spina E, Avenoso A, Facciolà G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit. 2001;23:223-227. (Pubitemid 32476548)
14. Saito M, Yasui-Furukori N, Nakagami T, et al. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients. J Clin Psychopharmacol. 2005;25:527-532. (Pubitemid 41669043)
15. Waade RB, Christensen H, Rudberg I, et al. Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole. Ther Drug Monit. 2009;31:233-238.
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revision. Washington, DC: American Psychiatric Association; 2000.
17. Kubo M, Koue T, Maune H, et al. Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet. 2007; 22:358-366.
18. Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised. In: Publication 76-338. Rockville, MD: US Department of Health, Education and Welfare; 1976.
19. Inada T, Yagi G, Miura S. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated olanzapine or haloperidol. Schizophr Res. 2002;57:227-238. (Pubitemid 35240025)
20. Kubo M, Mizooku Y, Hirao Y, et al. Development and validation of an LC-MS/MS method for the quantitative determination of aripiprazole and its main metabolite, OPC-14857, in human plasma. J Chromatography B. 2005;822:294-299. (Pubitemid 40994064)
21. Steen VM, Andreassen OA, Daly AK, et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics. 1995;5:215-223.
22. Heim M, Meyer U. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet. 1990;336;529-532. (Pubitemid 20278099)
23. Johansson I, Oscarson M, Yue QY, et al. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol. 1994;46:452-459. (Pubitemid 24296678)
24. Kubota T, Yamaura Y, Ohkawa N, et al. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol. 2000;50:31-34. (Pubitemid 30416968)
25. Sakuyama K, Sasaki T, Ujiie S, et al. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). Drug Metab Dispos. 2008;36:2460-2467.
26. Mihara K, Kondo T, Yasui-Furukori N, et al. Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia. Ther Drug Monit. 2003;25: 287-293. (Pubitemid 36638171)
27. Fujishiro J, Imanishi T, Onozawa K, et al. Comparison of the anticholinergic effects of the serotonergic antidepressants, paroxetine, fluvoxamine and clomipramine. Eur J Pharmacol. 2002;454: 183-188. (Pubitemid 35287477)